Jubilant Life Sciences receives ANDA approval
It is the generic version of Aldactone (of GD Searle), which is used as a diuretic to treat fluid retention (edema) caused by congestive heart failure and cirrhosis of the liver.
"We expect to launch this product in Q1 FY15.The total market size for Spironolactone Tabletsas per IMS is US$ 87Million per annum," the compamy said.
Jubilant has also received a tentative approval from the USFDA for Memantine Tablets, 5 mg and 10 mg, the generic version of Namenda (of Forest Labs), which is used for treatment of moderate-to-severe Alzheimer’s disease.
"We expect to launch this product post patent expiry in 2015. The total market size for Namenda as per IMS is US$ 1.85 Billion per annum," the company said.
As on December 31, 2013, Jubilant Life Sciences had a total of 689 filings for formulations of which 230 have been approved in various regions globally.
This includes 60 ANDAs filed in the US and 42 Dossier filings in Europe.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
